Objective: To investigate risk factors to predict left atrial or left atrial appendage thrombus in non-valvular atrial fibrillation patients. Methods: The study was a retrospective cohort study in which 204 consecutive non-valvular AF patients were enrolled, 11 patients in mismatch condition were abandoned, and all patients were divided into LA/LAA thrombus group(n=22)and non LA/LAA thrombus group(n=191). Patients’ medical history, general conditions, laboratory test results, transthoracic echocardiography(TTE) and transesophagel echocardiography(TEE) results were recorded in detail, and then CHADS2 score was calculated. Results:(1)One hundred and ninety three patients were enrolled, male 116 cases, female 77 cases, with an average age of (61.38 ± 9.58) years. Paroxysmal atrial fibrillation(AF) 150 cases (77.9%), persistent / permanent AF 43 cases (22.1% ), the LA/LAA thrombus confirmed by 3D transesophageal echocardiography were 22 cases (11.4%), non-thrombotic group 171 cases (88.6%). (2) No significant differences were found between two groups at age, BMI, drinking history, hypertension, diabetes mellitus, stroke or TIA, course of AF(P>0.05). The proportion of male, smoking history, persistent and permanent AF, left atrial spontaneous echo contrast(SEC), left atrial diameter (LAD), uric acid (UA) levels were significantly higher in thrombosis group(P<0.05).However,the CHADS2 score had no significant difference between two groups(P>0.05). (3)Multivariate Logistic regression analysis demonstrated that LAD(OR=1.115,95%CI: 1.011~1.011,P=0.029), persistent and permanent AF(OR=0.319,95%CI: 0.108~0.938,P=0.038), SEC(OR=0.200,95%CI: 0.066~0.602,P=0.004)were independent risk factors for LA/LAA thrombus. Conclusion: LAD expansion, persistent and permanent AF and SEC are high-risk factors for LA / LAA thrombus formation.
[1]Chugh S S, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation a global burden of disease 2010 study[J].Circulation,2014,129(8):837
[2]Fang M C, Go A S, Chang Y, et al. Comparison of risk stratification schemes to predict thromboembolism in People with nonvalvular atrial fibrillation[J]. J Am Coll Cardiol,2008,51(8):810
[3]Stollberger C, Chnupa P, Kronik G, et al. Transesophageal echocardiography to assess embolic risk in patients with atrial fibrillation. ELAT Study Group.Embolism in Left Atrial Thrombi[J]. Ann Intern Med,1998,128(8):630
[4]Camm A J, Kirchhof P, Lip G Y, et al. Guidelines for the management of atrial fibrillation The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)[J]. Europace, 2010,12(10):1360
[5]Demir K, Can I, Koc F, et al. Atorvastatin given prior to electrical cardioversion does not affect the recurrence of atrial fibrillation in patients with persistent atrial fibrillation who are on antiarrhythmic therapy[J]. Med Princ Pract, 2011,20(5):464
[6]Go A S, Hylek E M, Phillips K A, et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study[J]. JAMA,2001,285(18):2370
[7]Di Angelantonio E, Ederhy S, Benyounes N, et al.Comparison of transesophageal echocardiographic identification of embolic risk markers in patients with lone versus non-lone atrial fibrillation[J].Am J Cardiol,2005,95(5):592
[8]朱梦云,于学靖,彭文辉,等.经食道超声心动图对心房颤动围手术期脑卒中临床价值的研究[J]. 同济大学学报:医学版,2012,33(3):100
[9]Calvo N, Mont L, Vidal B, et al. Usefulness of transoesophageal echocardiography before circumferential pulmonary vein ablation in patients with atrial fibrillation: is it really mandatory?[J]. Europace, 2011,13(4):486
[10]Scherr D, Dalal D, Chilukuri K, et al. Incidence and predictors of left atrial thrombus prior to catheter ablation of atrial fibrillation[J]. J Cardiovasc Electrophysiol, 2009,20(4):379
[11]王志荣, 张超群, 程仁力,等. 心房颤动患者血小板活化与左心房血栓形成关系的研究[J].中国循环杂志, 2008,23(4):253
[12]Rampling M W, Meiselman H J, Neu B, et al. Influence of cell-specific factors on red blood cell aggregation[J]. Biorheology, 2004,41(2):91
[13]Conway D S, Buggins P, Hughes E, et al. Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation[J]. Am Heart J, 2004,148(3):462
[14]汤日波,刘畅,马长生,等.年龄对非瓣膜病心房颤动患者左心房血栓的影响[J]. 中华老年心脑血管病杂志, 2010,12(3):212
[15]Yarmohammadi H, Klosterman T, Grewal G, et al. Efficacy of the CHADS? scoring system to assess left atrial thrombogenic milieu risk before cardioversion of non-valvular atrial fibrillation[J]. Am J Cardiol, 2013,112(5):678
[1]陈延勋,李广平. 非瓣膜性心房颤动患者尿酸与CHADS2、CHA2DS2-VASc评分的关系[J].天津医科大学学报,2015,21(03):185.
CHEN Yan-xun,LI Guang-ping. Relationship between uric acid and CHADS2/CHA2DS2-VASc Score in patients with nonvalvular atrial fibrillation[J].Journal of Tianjin Medical University,2015,21(02):185.
[2]崔占前,徐延敏.脂蛋白相关性磷脂酶A2及高敏C反应蛋白与左心房内径的关系[J].天津医科大学学报,2015,21(03):196.
CUI Zhan-qian,XU Yan-min.Relationship between plasma lipoprotein-associated phospholipase A2, high sensitivity C reactive protein and left atrial diameter[J].Journal of Tianjin Medical University,2015,21(02):196.
[3]付伟伟,李国东,王 喆.HDL-C与非瓣膜性心房颤动左心房/左心耳血栓形成的关系[J].天津医科大学学报,2015,21(06):498.
FU Wei-wei,LI Guo-dong,WANG Zhe.Relationship between high-density lipoprotein cholesterol and left atrial / left atrial appendage thrombus in non-valvular atrial fibrillation patients[J].Journal of Tianjin Medical University,2015,21(02):498.
[4]张彦月,林文华.vWF及血浆D-二聚体水平对非瓣膜性心房颤动患者血栓形成的诊断及临床预后价值[J].天津医科大学学报,2016,22(02):101.
ZHANG Yan-yue,LIN Wen-hua.Value of vWF and?D-dimer for thrombosis and prognosis in patients with non-valvular atrial fibrillation[J].Journal of Tianjin Medical University,2016,22(02):101.
[5]刘运龄,赵艳淑,刘恩照,等.不同类型心房颤动患者心脏结构及B型钠尿肽水平的变化[J].天津医科大学学报,2016,22(06):522.
LIU Yun-ling,ZHAO Yan-shu,LIU En-zhao,et al.Relationship between plasma leves B-type natriuretic peptide and cardiac structure in patients with different types of atrial fibrillation[J].Journal of Tianjin Medical University,2016,22(02):522.
[6]张邦滢 综述,李广平 审校.新型抗心律失常药物在心房颤动中的应用[J].天津医科大学学报,2017,23(01):90.
[7]张凤环,上官文锋,王学文,等.血管紧张素-(1-7)对快速心房起搏犬心房重构及p38MAPK蛋白表达的影响[J].天津医科大学学报,2019,25(05):450.
ZHANG Feng-huan,SHANGGUAN Wen-feng,WANG Xue-wen,et al.Effect of angiotensin-(1-7) on atrial remodeling and p38MAPK expression in a canine model of rapid atrial pacing[J].Journal of Tianjin Medical University,2019,25(02):450.
[8]杜春蕾,郭 牧,张云强,等.尼非卡兰和胺碘酮治疗急性心肌梗死新发房颤有效性和安全性对比研究[J].天津医科大学学报,2019,25(05):471.
DU Chun-lei,GUO Mu,ZHANG Yun-qiang,et al.Comparison of nifekalant and amiodarone in the treatment of new-onset atrial fibrillation in acute myocardial infarction patients[J].Journal of Tianjin Medical University,2019,25(02):471.
[9]张茂芃,陈炳伟,卢成志,等.脉冲场消融治疗心房颤动的短期及长期安全性临床研究[J].天津医科大学学报,2023,29(06):636.
ZHANG Mao-peng,CHEN Bing-wei,LU Cheng-zhi,et al.The short-term and long-term safety clinical trial of pulse field ablation to treat atrial fibrillation[J].Journal of Tianjin Medical University,2023,29(02):636.